🔍

IKS - Inventurus Knowl

📊 NSE: IKS 🏢 Computers - Software - Medium / Small 📅 Last Updated: 12/14/2025 8:25

📢 Recent Corporate Announcements

Inventurus Knowledge Solutions to Invest USD 40 Million in US Subsidiary IKS Inc.

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 13 Mar 2026, 08:20 PM

Inventurus Knowledge Solutions (IKS) has approved a further investment of up to USD 40 million in its wholly-owned US subsidiary, IKS Inc. The investment will be conducted in tranches, with the first USD 20 million tranche expected to be completed by May 31, 2026, at a price of USD 643.19 per share. IKS Inc. is a key revenue driver for the company, reporting a turnover of INR 6,941.11 million in FY 2024-25. This capital infusion is aimed at supporting the subsidiary's business activities in the US healthcare technology sector.

Total investment of up to USD 40 million approved for US-based subsidiary IKS Inc.
First tranche of USD 20 million involves acquiring 31,096 shares at USD 643.19 each.
IKS Inc. reported FY 2024-25 revenue of INR 6,941.11 million, showing stable performance.
The investment is expected to be completed by May 31, 2026, through cash consideration.
IKS Inc. provides technology-enabled care enablement platforms for US healthcare providers.

💡 Investors should monitor the utilization of this capital for potential technology upgrades or market expansion in the US. The continued focus on the US healthcare market remains a core growth driver for the company.

Inventurus Knowledge Solutions Faces INR 17.45 Lakh Penalty from SEEPZ Development Commissioner

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 12 Mar 2026, 08:11 PM

Inventurus Knowledge Solutions (IKS) has been penalized INR 17,44,894 by the Office of the Development Commissioner, SEEPZ-SEZ, Mumbai. The penalty relates to the classification of services under CPC codes for availing Service Exports from India Scheme (SEIS) benefits during the financial years 2015-16 to 2018-19. The company received the formal order on March 12, 2026. Management has clarified that this order will not have any material impact on the company's financial or operational activities.

Penalty of INR 17,44,894 imposed by the Ministry of Commerce & Industry authority
Issue involves misclassification of services for SEIS benefits between FY 2015-16 and FY 2018-19
Order received and disclosed by the company on March 12, 2026
Company confirms no significant impact on operations or financial standing

💡 The penalty amount is relatively small and pertains to historical filings, suggesting no major risk to current operations. Investors should treat this as a routine regulatory disclosure with minimal impact on the stock's valuation.

IKS Grants 600,000 Employee Stock Options at Exercise Price of Rs. 1,331

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 05 Mar 2026, 11:27 AM

Inventurus Knowledge Solutions (IKS) has approved the grant of 600,000 employee stock options to eligible employees under its 2022 ESOP Plan. Each option is convertible into one equity share of face value Re. 1 at an exercise price of Rs. 1,331.00, which matches the market price as of March 4, 2026. The plan is administered through a trust, and the resulting shares will not have a lock-in period upon exercise. This move is a standard corporate procedure aimed at incentivizing and retaining key talent within the organization.

Grant of 600,000 employee stock options under the IKS ESOP Plan 2022
Exercise price set at Rs. 1,331.00 per share, based on the NSE closing price of March 4, 2026
Each option converts into one fully paid-up equity share of Re. 1 face value
The scheme is administered via a Trust and shares issued will have no lock-in period
The grant was approved by the Nomination and Remuneration Committee on March 5, 2026

💡 This is a routine corporate action for talent retention with minimal immediate impact on share value. Investors should monitor the cumulative ESOP pool to assess potential long-term equity dilution.

IKS Grants 54,000 Employee Stock Options at Exercise Price of Rs 1,540.20

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Feb 2026, 01:06 PM

Inventurus Knowledge Solutions Limited (IKS) has approved the grant of 54,000 employee stock options under its 2022 ESOP Plan. These options are exercisable into an equal number of equity shares with a face value of Re. 1 each. The exercise price is set at Rs. 1,540.20, which aligns with the market price on the National Stock Exchange as of February 23, 2026. This move is aimed at incentivizing and retaining eligible employees through the company's trust-administered plan.

Grant of 54,000 employee stock options to eligible employees under the IKS ESOP Plan 2022.
Exercise price fixed at Rs. 1,540.20 per option, based on the market closing price of February 23, 2026.
Each option is convertible into one fully paid-up equity share of face value Re. 1.
The plan is administered through a Trust, and shares issued upon exercise will not have a lock-in period.

💡 This is a routine administrative announcement regarding employee compensation. No action is required as the potential equity dilution from 54,000 shares is negligible.

IKS Grants 75,000 Employee Stock Options at Exercise Price of Rs 1,658.40

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 12:55 PM

Inventurus Knowledge Solutions Limited (IKS) has approved the grant of 75,000 employee stock options under its 2022 ESOP Plan. Each option is convertible into one equity share of face value Re. 1 at an exercise price of Rs. 1,658.40, which matches the market price as of February 19, 2026. The grant is intended to incentivize and retain eligible employees through equity-based compensation. This is a standard corporate procedure and the total number of shares involved is relatively small.

Grant of 75,000 stock options to eligible employees under the IKS ESOP Plan 2022
Exercise price fixed at Rs. 1,658.40 per option based on the NSE closing price
Each option is convertible into one fully paid-up equity share of face value Re. 1
The scheme is administered through a Trust and shares will have no lock-in period post-exercise

💡 This is a routine administrative matter for talent retention with minimal equity dilution. No immediate action is required from investors.

IKS Reports 24% YoY Revenue Growth in Q3 FY26 with Minimal 1.5% Headcount Increase

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 06:21 PM

Inventurus Knowledge Solutions (IKS) reported a strong Q3 FY26 with 24% YoY revenue growth in Rupee terms and 19% in Dollar terms. The company demonstrated significant operational leverage, achieving this growth with only a 1.5% increase in headcount (13,350 total), highlighting its successful transition to an AI-native platform. IKS is currently outperforming the outsourced healthcare market growth of 12%, indicating substantial market share gains. Management emphasized progress in autonomous clinical documentation and medical coding solutions to further decouple revenue from labor costs.

Revenue grew 24% YoY in INR terms and 19% in USD terms for the quarter ended December 31, 2025.
Headcount increased by only 1.5% YoY to 13,350, demonstrating a break in linearity between revenue and people growth.
Company is growing at double the rate of the $35 billion outsourced healthcare market, which grows at 12% annually.
Successfully deployed AI-native agentic workflows for clinical documentation, medical coding, and prior authorization.
Targeting a total addressable market (TAM) of $260 billion in US healthcare administrative tasks.

💡 Investors should view the decoupling of headcount from revenue as a significant margin expansion catalyst. The company's ability to outpace market growth while maintaining a flat workforce suggests a strong competitive moat in AI-led healthcare services.

IKS Releases Q3 FY 2025-26 Earnings Conference Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 05 Feb 2026, 03:44 PM

Inventurus Knowledge Solutions Limited (IKS) has officially released the audio recording of its Earnings Conference Call for the third quarter of FY 2025-26. The call, which took place on February 5, 2026, followed the announcement of the company's quarterly financial results. This disclosure is a routine regulatory requirement under SEBI's Listing Obligations and Disclosure Requirements. Investors can now access the full management commentary and the Q&A session via the company's investor relations website.

Audio recording of the Q3 FY 2025-26 earnings call is now available for public access.
The conference call was held on Thursday, February 5, 2026.
Compliance maintained with SEBI Regulation 30 and 46 (2)(oa) regarding disclosure of investor meets.
Direct access link provided to the MP3 recording on the company's official website.

💡 Investors should listen to the recording to understand management's perspective on Q3 performance and future growth guidance. Pay close attention to the Q&A section for insights into operational challenges or market expansion plans.

IKS Q3 FY26: Revenue Up 24% YoY to ₹8,150 Mn; PAT Surges 41% with Strong Margin Expansion

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 09:03 PM

Inventurus Knowledge Solutions (IKS) reported a strong Q3 FY26 with revenue rising 24% YoY to ₹8,150 million and PAT increasing 41.4% to ₹1,833 million. The company achieved an impressive EBITDA margin of 34.6%, up from 30.5% in the same quarter last year. Cash flow generation remains robust, with Free Cash Flow (FCF) growing 79.9% YoY, while net debt was significantly reduced to ₹1,455 million. Key deal wins with VitalMD and StrideCare highlight continued momentum in the US healthcare enablement market.

Revenue from operations reached ₹8,150 million, a 24% YoY increase (19% in USD terms).
EBITDA grew 40.4% YoY to ₹2,816 million, maintaining a high margin of 34.6%.
Adjusted PAT stood at ₹2,154 million, up 48% YoY, after accounting for non-recurring debt refinancing costs.
Net debt decreased sharply to ₹1,455 million from ₹4,159 million YoY, strengthening the balance sheet.
The company reported a high Return on Equity (ROE) of 31% and an EPS of ₹11 for the quarter.

💡 The company demonstrates strong fundamental growth and efficient capital management; investors should monitor the scalability of its AI-native platform and client retention as key growth drivers.

IKS Health Q3 FY26: Revenue up 24% to INR 8,150 Mn, PAT Surges 41% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 08:53 PM

Inventurus Knowledge Solutions (IKS Health) reported a robust Q3 FY26 with revenue reaching INR 8,150 Mn, a 24% YoY increase. Net profit (PAT) grew significantly by 41% YoY to INR 1,833 Mn, supported by strong EBITDA margins of 35%. The company continues to benefit from US healthcare outsourcing trends and expanded partnerships with major entities like StrideCare and a top 5 health system. Management's focus on AI-driven care enablement platforms is driving both top-line growth and operational efficiency.

Revenue increased 24% YoY to INR 8,150 Mn; PAT rose 41% YoY to INR 1,833 Mn.
EBITDA grew 40% YoY to INR 2,816 Mn with a healthy margin of 35% compared to 31% in Q3 FY25.
Expanded long-term partnership with VitalMD for AI-driven Scribble Suite solutions across 800+ providers.
New partnership with StrideCare for end-to-end revenue cycle management and clinical coding.
Expanded RCM and Value-Based Care partnership with a top 5 US health system into additional regions.

💡 The strong financial performance and margin expansion suggest high scalability and operating leverage; investors should maintain a positive outlook. Monitor the continued adoption of AI-driven 'Scribble Suite' as a key differentiator for long-term growth.

IKS Reports 24% YoY Revenue Growth to ₹8,149.5 Million in Q3 FY26

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 04 Feb 2026, 08:25 PM

Inventurus Knowledge Solutions (IKS) reported a strong consolidated revenue of ₹8,149.5 million for the quarter ended December 31, 2025, representing a 24% increase compared to the same quarter last year. The company's nine-month revenue reached ₹23,361.36 million, up from ₹19,400.38 million in the previous year, showing consistent growth. While revenue grew, employee benefit expenses also rose to ₹4,059.09 million, reflecting the scale-up in operations. The standalone revenue showed even more significant growth, jumping nearly 67% YoY to ₹4,035.28 million.

Consolidated revenue from operations grew 24% YoY to ₹8,149.50 million in Q3 FY26.
Nine-month consolidated revenue reached ₹23,361.36 million, compared to ₹19,400.38 million in the prior year period.
Standalone revenue for the quarter surged 67% YoY to ₹4,035.28 million from ₹2,413.13 million.
Total consolidated income for Q3 FY26 stood at ₹8,205.03 million versus ₹6,841.50 million in Q3 FY25.
Employee benefit expenses for the quarter were ₹4,059.09 million, up from ₹3,833.74 million in the previous year's quarter.

💡 Investors should focus on the company's ability to maintain margins as it scales, given the rising employee and finance costs. The strong top-line growth indicates healthy demand for its healthcare-focused knowledge solutions.

IKS to Participate in Axis Capital Conference 2026 on February 10

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Feb 2026, 07:33 PM

Inventurus Knowledge Solutions Limited (IKS) has announced its participation in the Axis Capital Conference 2026 scheduled for February 10, 2026. The event will be held in Mumbai from 9:00 AM to 5:00 PM IST and involves meetings with multiple institutional investors. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these interactions. This is a routine disclosure as per SEBI listing regulations to maintain transparency with the investor community.

Scheduled to attend the Axis Capital Conference 2026 in Mumbai on February 10, 2026.
The engagement will involve multiple institutional investors throughout the day from 09:00 AM to 05:00 PM IST.
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the meet.
The schedule is subject to change based on exigencies from either the company or the investors.
Disclosure made under Regulation 30(6) of SEBI (LODR) Regulations, 2015.

💡 Investors should monitor for any investor presentations or transcripts released after the conference for insights into the company's growth outlook. No immediate action is required as this is a routine communication.

Inventurus Knowledge Solutions to Attend Nuvama India Conference on February 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 03 Feb 2026, 07:30 PM

Inventurus Knowledge Solutions Limited (IKS) has announced its participation in the Nuvama India Conference 2026 scheduled for February 9, 2026, in Mumbai. The company will engage with multiple institutional investors between 09:00 AM and 05:00 PM IST to discuss business prospects. Management has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these meetings. This interaction is part of the company's routine investor relations outreach to maintain transparency with the financial community.

Scheduled to participate in the Nuvama India Conference 2026 on February 9, 2026.
The event involves meetings with multiple institutional investors in Mumbai.
Interaction window is set from 09:00 AM to 05:00 PM IST.
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be disclosed.

💡 Investors should watch for any corporate presentations or meeting transcripts filed after the conference for insights into the company's strategic direction. No immediate trading action is necessary based on this routine disclosure.

IKS Grants 122,000 Employee Stock Options at Exercise Price of Rs. 1,537.10

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Jan 2026, 01:00 PM

Inventurus Knowledge Solutions Limited (IKS) has approved the grant of 122,000 employee stock options under its 2022 ESOP Plan. Each option is convertible into one equity share of face value Re. 1, with the exercise price set at Rs. 1,537.10 per share. This price aligns with the market closing price on the National Stock Exchange as of January 29, 2026. The grant is a standard corporate procedure aimed at talent retention and aligning employee interests with long-term shareholder value.

Grant of 122,000 employee stock options to eligible employees under the IKS ESOP Plan 2022.
Exercise price fixed at Rs. 1,537.10 per option, matching the market price on January 29, 2026.
Each option entitles the holder to one fully paid-up equity share of face value Re. 1.
The ESOP plan is administered through a Trust and shares issued upon exercise will have no lock-in period.
The grant was approved by the Nomination and Remuneration Committee on January 30, 2026.

💡 This is a routine administrative announcement regarding employee compensation; no immediate action is required as the equity dilution is minimal.

Inventurus Knowledge Solutions to Hold Q3 FY26 Earnings Call on February 5, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 27 Jan 2026, 08:15 PM

Inventurus Knowledge Solutions Limited (IKS) has scheduled its earnings conference call for the third quarter of FY 2025-26 on February 5, 2026, at 8:30 AM IST. The call will provide management's perspective on the financial results for the quarter ending December 31, 2025. Investors can join via universal dial-in numbers +91 22 6280 1144 or +91 22 7115 8045. This is a routine regulatory disclosure under SEBI LODR Regulations to facilitate investor interaction.

Earnings conference call for Q3 FY 2025-26 scheduled for February 5, 2026, at 8:30 AM IST
Universal dial-in numbers provided: +91 22 6280 1144 and +91 22 7115 8045
International toll-free numbers available for USA (1 866 746 2133) and UK (0 808 101 1573)
Diamond Pass registration link provided for priority access to the call
Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

💡 Investors should mark the date to listen to management's commentary on revenue growth and operational margins. Key focus should be on any updates regarding client acquisitions or expansion in the healthcare solutions space.

IKS Grants 525,000 Employee Stock Options Under ESOP Plan 2022

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 22 Jan 2026, 11:42 AM

Inventurus Knowledge Solutions Limited (IKS) has approved the grant of 525,000 employee stock options to eligible employees on January 22, 2026. The grant is split into two categories: 420,000 options at an exercise price of Rs. 1,664.30 and 105,000 options at a discounted price of Rs. 320.00. Each option is convertible into one equity share of face value Re. 1. This move is part of the company's long-term strategy to retain talent and align employee interests with shareholder growth.

Total grant of 525,000 stock options approved by the Nomination and Remuneration Committee.
420,000 options granted at an exercise price of Rs. 1,664.30, matching the market price.
105,000 options granted at a significantly lower exercise price of Rs. 320.00.
Each option converts into one fully paid-up equity share of Re. 1 face value.
The ESOP scheme is administered through a Trust and includes provisions for corporate actions like splits or bonuses.

💡 Investors should note this as a routine talent retention measure, though they should monitor the eventual equity dilution when these options are exercised. No immediate impact on stock performance is expected from this announcement.

View All IKS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 21.5% YoY to INR 781.1 Cr in Q2 FY26, driven by a 22% increase in the AQuity delivery model and cross-selling initiatives. H1 FY26 revenue reached INR 1,521.2 Cr, an 18.6% increase over H1 FY25.

Geographic Revenue Split

The company primarily serves the U.S. healthcare market, with operations managed through four entities: IKS India, IKS US, AQuity US, and AQuity India. Specific regional percentage splits are not disclosed, but growth is driven by U.S.-based Physician Enterprises.

Profitability Margins

Net Profit Margin for FY25 was 18.25%, a decrease from 20.38% in FY24 due to higher amortization of acquired intangibles and increased finance costs. However, Q2 FY26 PAT reached INR 181 Cr, representing a 60% YoY growth and a 19% QoQ increase.

EBITDA Margin

Adjusted EBITDA margin reached 36.0% in Q2 FY26, up from 30.4% in Q2 FY25 (a 5.6% improvement). This margin expansion was achieved 3-4 quarters ahead of management's internal timeline due to AI-driven human intervention reduction and operational transformation of AQuity.

Capital Expenditure

Not explicitly disclosed in absolute INR Cr for future periods, but the company is prioritizing organic growth through R&D, which has increased from 3.5% to nearly 5% of EBITDA.

Credit Rating & Borrowing

The Debt-Equity ratio significantly improved, decreasing 59.07% from 1.03 in FY24 to 0.42 in FY25, primarily due to debt repayment from internal accruals. The company aims to be net debt-free by FY27.

⚙️ Operational Drivers

Raw Materials

Human Capital (Employee Benefit Expenses) represents the primary cost, accounting for INR 397.4 Cr or 50.8% of revenue in Q2 FY26.

Import Sources

Talent is primarily sourced from India and the United States to support the global delivery model.

Key Suppliers

Not applicable as a service-based healthcare technology firm; primary 'suppliers' are the global workforce and technology infrastructure providers.

Capacity Expansion

The sales and marketing organization has been expanded to 61+ employees to drive market reach. Capacity is managed through headcount optimization and AI-driven productivity gains.

Raw Material Costs

Employee benefit expenses (excluding ESOP) grew 10.8% YoY to INR 397.4 Cr in Q2 FY26, which is lower than the 21.5% revenue growth, indicating improved operational leverage.

Manufacturing Efficiency

Adjusted EBITDA per employee (annualized) improved to INR 0.91 Mn in Q2 FY26 from INR 0.56 Mn in Q2 FY25, reflecting a significant increase in per-capita productivity.

Logistics & Distribution

Not applicable; services are delivered digitally via a care enablement platform.

📈 Strategic Growth

Expected Growth Rate

27.90%

Growth Strategy

Growth is driven by a transition to a 'Net Economic Value Added' (NEVA) model where IKS shares in the client's EBITDA improvements. Strategy includes cross-selling IKS solutions to the acquired AQuity customer base, aggressive R&D in AI to reduce human intervention, and expanding the Go-To-Market engine which now has 61+ dedicated employees.

Products & Services

Care enablement platform, clinical documentation, revenue cycle management, and margin-optimized growth strategies for Physician Enterprises.

Brand Portfolio

IKS Health, AQuity Solutions.

New Products/Services

AI-integrated features within the care enablement platform are expected to drive margins toward the mid-30s percentage range.

Market Expansion

Focusing on deep penetration of the U.S. Physician Enterprise market through strategic partnerships like those with Palomar and Western Washington Medical Group.

Market Share & Ranking

Not disclosed in available documents, but management describes the market as 'early-stage' with a 'very long runway'.

Strategic Alliances

Strategic partnership with Palomar Health involving a value-based model where IKS recovers investment through shared economic value over 3-4 years.

🌍 External Factors

Industry Trends

The industry is shifting from labor-arbitrage (FTE-based) to technology-enabled outcome models. IKS is positioning itself as a strategic partner rather than a vendor, leveraging AI to co-monetize value with clients.

Competitive Landscape

Competes with traditional healthcare BPO providers and emerging AI-healthtech firms; differentiates through deep clinical integration and outcome-linked commercial frameworks.

Competitive Moat

Moat is built on high switching costs (average client tenure of 6-7 years) and a unique value-based pricing model (NEVA) that aligns IKS's revenue with client EBITDA improvements, making it difficult for traditional FTE-based competitors to displace.

Macro Economic Sensitivity

Sensitive to U.S. healthcare spending and regulatory changes; however, the outcome-based model provides some insulation by aligning with client profitability.

Consumer Behavior

U.S. healthcare providers are increasingly seeking 'value-based' contracts and margin-optimized growth, driving demand for IKS's comprehensive platform.

Geopolitical Risks

Exposure to trade regulations and data privacy laws between India and the U.S. given the cross-border service delivery model.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with U.S. healthcare regulations (HIPAA implied) and SEBI SBEB Regulations for employee stock options. The company maintains a system of internal financial controls to ensure compliance with applicable statutes.

Environmental Compliance

Not a material factor disclosed for this service-based business.

Taxation Policy Impact

The company faced a higher effective tax rate in FY25, which contributed to the decrease in net profit margin from 20.38% to 18.25%.

Legal Contingencies

No specific pending court case values in INR were disclosed; however, the company notes that actual results may differ due to changes in government regulations and tax laws.

⚠️ Risk Analysis

Key Uncertainties

Technological disruption from AI and machine learning requires constant innovation; failure to update the platform could lead to obsolescence.

Geographic Concentration Risk

High concentration in the U.S. healthcare market; economic or regulatory shifts in U.S. healthcare policy would have a direct impact on 100% of core operations.